Simplexia is develops vaccine against herpes simplex virus type (HSV-2) infection, which is the most common sexually transmitted infection in the world. The infection causes genital herpes with painful and recurrent genital blisters. HSV-2 can also cause life-threatening encephalitis and meningitis in newborns and immunocompromised patients. A major issue is that HSV-2 infected patients also suffer a three-fold increased risk of HIV acquisition.
| Website | http://www.simplexia.se |
| Employees | 5 (3 on RocketReach) |
| Address | Nanna Svartz väg 2, Stockholm, Stockholm County 17165, SE |
| Technologies | |
| Industry | Biotechnology Research |
| Keywords | Vaccine Development, Viral Infection Treatment, Pharmaceutical Research, Biotechnology, Drug Discovery, Infectious Disease, Medical Research, Vaccine Research, Therapeutic Development, Clinical Trials, Health Technology, Antiviral Drugs, Pharmaceutical, Immunology |
| Competitors | Zoho, Bill.com, SAP Concur, Basware, Medius, Spendesk, Sage Intacct, Inc., Expensify, Tradeshift, Divvy +35 more (view full list) |
Looking for a particular Simplexia employee's phone or email?
Simplexia Questions
Nina Lindblom is the CEO of Simplexia.
3 people are employed at Simplexia.
Simplexia is based in Stockholm, Stockholm County.
Top Simplexia Employees
Related Companies
